Q1 FY2027 · ended Jul 31, 2026 · Revenue $2,100 · Filed Sep 14, 2026
HeartSciences Inc. (HSCS) files with the SEC under industry code 6199, Finance Services. In Q1 of fiscal 2027, the quarter ended Jul 31, 2026, it reported revenue of $2,100 and a net loss of $3.2 million. As of Jul 31, 2026 it held $29,906 in cash and investments and $281,570 in total debt.
Revenue
$2,100
Net income
$-3.17M
-15.3% vs prior quarter
Operating cash flow
$-1.32M
+21.3% vs prior quarter
Free cash flow
$-1.68M
-5.4% vs year-ago quarter
EPS
$-1.95
+30.5% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
4.80M
+23.1% vs prior quarter
Net cash
$-251,664
Q1 FY2027
Operating margin
-139956.7%
Q1 FY2027
Company profile
- Industry
- Finance Services (SIC 6199)
- Listed as
- HSCS (Nasdaq), HSCSW (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- TX
- Headquarters
- Southlake, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1468492
- Former names
- Heart Test Laboratories, Inc. (until Oct 18, 2024)
Other Finance Services companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jul 31, 2026 |
Q4 FY2026 Apr 30, 2026 |
Q3 FY2026 Jan 31, 2026 |
Q1 FY2025 Jul 31, 2025 |
Q4 FY2025 Apr 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $2,100 | $0 | $0 | $1,900 | -$14,250 |
| Operating income | -$2.9M | -$2.5M | -$1.9M | -$1.9M | -$1.9M |
| Net income | -$3.2M | -$2.8M | -$2.0M | -$2.1M | -$2.1M |
| Diluted EPS | — | — | — | — | -$1.95 |
| Operating cash flow | -$1.3M | -$1.7M | -$5.8M | -$2.0M | -$1.6M |
| Free cash flow | — | -$1.7M | -$5.8M | — | -$1.6M |
| Total assets | $3.7M | — | $7.6M | $6.4M | $4.2M |
| Total liabilities | $5.8M | — | $4.9M | $3.3M | $4.0M |
| Stockholders' equity | -$2.0M | — | $2.7M | $3.1M | $205,171 |
| Cash and investments | $29,906 | — | $3.4M | $2.8M | $1.1M |
| Total debt | $281,570 | — | $345,844 | $405,743 | $434,045 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Oct 2, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Sep 14, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 20, 2026 | Aug 20, 2026 |
All 346 HeartSciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.